Raltegravir susceptibility and fitness progression of HIV type-1 integrase in patients on long-term antiretroviral therapy

Antiviral Therapy

Volumn 13, Issue 7, 2008, Pages 881-893

  Buzón, Maria José ^a   Marfil, Silvia ^a   Puertas, Maria C ^a   Garcia, Elisabet ^a   Clotet, Bonaventura ^a   Ruiz, Lidia ^a   Blanco, Julià ^a   Martinez Picado, Javier ^a,b   Cabrera, Cecilia ^a  

^a IrsiCaixa Foundation   (Spain)

^b INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; ENFUVIRTIDE; INTEGRASE; INTEGRASE INHIBITOR; LAMIVUDINE PLUS ZIDOVUDINE; PROTEINASE; PROTEINASE INHIBITOR; RALTEGRAVIR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; DRUG TARGETING; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; LONG TERM CARE; MALE; MOLECULAR EVOLUTION; MONOTHERAPY; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; VIRUS LOAD; VIRUS RECOMBINANT; VIRUS REPLICATION;

AMINO ACID SUBSTITUTION; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; EVOLUTION, MOLECULAR; GENOTYPE; HIV INFECTIONS; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; PYRROLIDINONES; RECOMBINATION, GENETIC; TIME FACTORS; VIRUS REPLICATION;

EID: 56749178876     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Donehower LA, Varmus HE. A mutant murine leukemia virus with a single missense codon in pol is defective in a function affecting integration. Proc Natl Acad Sci U S A 1984; 81:6461-6465.
2. Pommier Y, Johnson AA, Marchand C. Integrase inhibitors to treat HIV/ AIDS. Nat Rev Drug Discov 2005; 4:236-248.
3. Asante-Appiah E, Skalka AM. Molecular mechanisms in retrovirus DNA integration. Antiviral Res 1997; 36:139-156.
4. Van Maele B, Van Eylen L, Pluymers W, Debyser Z. Evaluation of the activity of HIV-1 integrase over-expressed in eukaryotic cells. Biochem Biophys Res Commun 2005; 327:261-267.
5. Hombrouck A, De Rijck J, Hendrix J, et al. Virus evolution reveals an exclusive role for LEDGF/p7S in chromosomal tethering of HIV. PLoS Pathog 2007; 3:47.
6. Bukrinsky MI, Sharova N, McDonald TL, Pushkarskaya T, Tarpley WG, Stevenson M. Association of integrase, matrix, and reverse transcriptase antigens of human immunodeficiency virus type 1 with viral nucleic acids following acute infection. Proc Natl Acad Sci U S A 1993; 90:6125-6129.
7. Esposito D, Craigie R. Sequence specificity of viral end DNA binding by HIV-1 integrase reveals critical regions for protein-DNA interaction. EMBO J 1998; 17:5832-5843.
8. Nymark-McMahon MH, Beliakova-Bethell NS, Darlix JL, Le Grice SE Sandmeyer SB. Ty3 integrase is required for initiation of reverse transcription. J Virol 2002; 76:2804-2816.
9. Padow M, Lai L, Deivanayagam C, et al. Replication of chimeric human immunodeficiency virus type I (HIV-1) containing HIV-2 integrase (IN): naturally selected mutations in IN augment DNA synthesis. J Virol 2003; 77:11050-11059.
10. Hehl EA, Joshi P, Kalpana GV, Prasad VR. Interaction between human immunodeficiency virus type 1 reverse transcriptase and integrase proteins. J Virol 2004; 78:5056-5067.
11. Este JA, Cabrera C, Schols D, et al. Human immunodeficiency virus glycoprotein gp120 as the primary target for the antiviral action of AR177 (Zintevir). Mol Pharmacol 1998; 53:340-345.
12. Grinsztejn B, Nguyen BY, Katlama C, et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 2007; 369:1261-1269.
13. Cooper D, Gatell J, Rockstroh J. Results of BENCHMRK-1, a phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. 14th Conference on Retroviruses and Opportunistic Infections. 25-29 February 2007, Los Angeles, CA, USA.
14. Steigbigel R, Kumar P, Eton J. Results of BENCHMRK-2, a phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. 14th Conference on Retroviruses and Opportunistic Infections. 25-29 February 2007, Los Angeles, CA, USA.
15. LaFemina RL, Schneider CL, Robbins HL, et al. Requirement of active human immunodeficiency virus type 1 trite rase enzyme for productive infection of human T-lymphM cells. J Virol 1992; 66:7414-7419.
16. Hazuda DJ, Felock P, Witmer M, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000; 287:646-650.
17. Fikkert V, Hombrouck A, Van Remoortel B, et al. Multiple mutations in human immunodeficiency virus-1 integrase confer resistance to the clinical trial drug S-1360. AIDS 2004; 18:2019-2028.
18. Hazuda DJ, Young SD, Guare JP, et al. Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. Science 2004; 305:528-532.
19. Hazuda DJ, Miller MD, Nguyen BY, Zhao Resistance to the HIV-integrase inhibitor raltegravir: analysis of protocol 005, a Phase II study in patients with triple-class resistant HIV- 1 infection. Antivir Ther 2007; 12 Suppl 1:S10.
20. Shimura K, Kodama E, Sakagami Y, et al. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J Virol 2008; 82:764-774.
21. McColl DJ, Fransen S, Gupta S, et al. Resistance and cross-resistance to first generation integrase inhibitors: insights from a Phase II study of elvitegarvir (GS-9137). Antivir Ther 2007; 12 Suppl 1:S11.
22. de Oliveira T, Deforche K, Cassol S, et al. An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics 2005; 21:3797-3800.
23. Los Alamos National Laboratory HIV Database Tools. (Updated 22 July 2008. Accessed 18 September 2008.) Available from www.hiv.lanl.gov.
24. Korber B. HIV signature and sequence variation analysis._In Computational analysis of HIV molecular sequences. Edited by AG Rodrigo & GH Learn. Dordrecht: Kluwer Academic Publishers 2000; pp. 55-72.
25. Gibbs JS, Regier DA, Desrosiers RC. Construction and in vitro properties of HIV-1 mutants with deletions in 'nonessential' genes. AIDS Res Hum Retroviruses 1994; 10:343-350.
26. Weber J, Weberova J, Carobene M, et al. Use of a novel assay based on intact recombinant viruses expressing green (EGFP) or red (DsRed2) fluorescent proteins to examine the contribution of pol and env genes to overall HIV-1 replicative fitness. J Virol Methods 2006; 136:102-117.
27. Li M, Gao E Mascola JR, et al. Montefiori, Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 2005; 79:10108-10125.
28. Fikkert V, Van Maele B, Vercammen J, et al. Development of resistance against diketo derivatives of human immunodeficiency virus type 1 by progressive accumulation of integrase mutations. J Virol 2003; 77:11459-11470.
29. Ceccherini-Silberstein F, Van Baelen K, Armenia D, et al. Novel HIV-1 integrase mutations, found as minority quasispecies in patients naïve to integrase inhibitors, are associated with decreased susceptibility to integrase inhibitors in vitro. 1Sth Conference on Retroviruses and Opportunistic Infections. 3-6 February 2008, Boston, MA, USA.
30. Skinner LM, Lamers SL, Sanders JC, Eyster ME, Goodenow MM, Katzman M. Analysis of a large collection of natural HIV-1 integrase sequences, including those from long-term nonprogressors. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 19:99-110.
31. Lataillade M, Chiarella J, Kozal MJ. Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance. Antivir Ther 2007; 12:563-570.
32. Reinke R, Steffen NR, Robinson WE. Natural selection results in conservation of HIV-1 integrase activity despite sequence variability. AIDS 2001; 15:823-830.
33. Kantor R, Shafer RW, Follansbee S, et al. Evolution of resistance to drugs in HIV-1-infected patients failing antiretroviral therapy. AIDS 2004; 18:1503-1511.
34. Kristiansen TB, Pedersen AG, Eugen-Olsen J, Katzenstein TL, Lundgren JD. Genetic evolution of HIV in patients remaining on a stable HAART regimen despite insufficient viral suppression. Scand J Infect Dis 2005; 37:890-901.
35. + T cell counts but persistent virologic failure. Clin Infect Dis 2005; 41:729-737.
36. Van Baelen K, Clynhens M, Rondelez E, et al. Low level of baseline resistance to integrase inhibitors L731,988 and L870,810 in randomly selected subtype B and non-B HIV-1 strains. Antivir Ther 2007; 12 Suppl 1:S7.
37. Malet I, Delelis O, Valantin A, et al. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob Agents Chemother 2008; 52:1351-1358.
38. Katz RA, Mack JP, Merkel G, et al. Requirement for a conserved serine in both processing and joining activities of retroviral integrase. Proc Natl Acad Sci U S A 1992; 89:6741-6745.
39. Ren C, May S, Miletti T, Bedard J. In vitro cross-resistance studies of five different classes of integrase inhibitors in recombinant HIV-1. Antivir Ther 2007; 12 Suppl 1:S3.
40. Cannon PM, Wilson W, Byles E, Kingsinan SM, Kingsman A Human immunodeficiency virus type 1 integrase: effect on viral replication of mutations at highly conserved residues. J Virol 1994; 68:4768-4775.
41. Wiskerchen M, Muesing MA. Human immunodeficiency virus type 1 integrase: effects of mutations on viral ability to integrate, direct viral gene expression from unintegrated viral DNA templates, and sustain viral propagation in primary cells. J Virol 1995; 69:376-386.
42. Zheng R, Jenkins TM, Craigie R. Zinc folds the N-terminal domain of HIV-1 integrase, promotes multimerization, and enhances catalytic activity. Proc Natl Acad Sci U S A 1996; 93:13659-13664.
43. Engelman A, Englund G, Orenstein JM, Martin MA, Craigie R. Multiple effects of mutations in human immunodeficiency virus type 1 integrase on viral replication. J Virol 199S; 69:2729-2736.
44. Troyer RM, Collins KR, Abraha A, et al. Changes in human immunodeficiency virus type 1 fitness and genetic diversity during disease progression. J Virol 2005; 79:9006-9018.
45. Ceccherini-Silberstein E, Malet I, Fabeni L, et al. Specific mutations related to resistance to HIV-1 integrase inhibitors are associated with reverse transcriptase mutations in HAART-treated patients. Antivir Ther 2007; 12 Suppl 1:S6.
46. Suzuki H, Fujino M, Matsuda M, Yen H, Iwantani Y, Sigiura W, Effects of protease and reverse transcriptase inhibitor-resistance mutations on integrase polymorphism in multidrug resistance cases. Antivir Ther 2007; 12 Suppl 1:S4.